CellSeed Inc. Logo

CellSeed Inc.

Develops cell sheet products, culture equipment, and offers contract manufacturing services.

7776 | T

Overview

Corporate Details

ISIN(s):
JP3423530009
LEI:
Country:
Japan
Address:
江東区青海2−5−10テレコムセンタービル15F
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CellSeed Inc. is a regenerative medicine company focused on the commercialization of its proprietary 'cell sheet engineering' technology, an innovative therapeutic approach originating in Japan. The company's core business involves the research, development, and manufacturing of cell sheet-based products to treat diseases and disorders. In addition to its therapeutic pipeline, CellSeed develops and sells specialized cell culture equipment and provides contracted development and manufacturing services for cell sheets. The company aims to deliver its novel medical treatments to patients globally, leveraging its expertise in cell culture and production to advance the field of regenerative medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 08:01
Registration Form
有価証券届出書(参照方式)
Japanese 154.6 KB
2025-08-14 08:48
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-14 08:47
Interim / Quarterly Report
半期報告書-第25期(2025/01/01-2025/12/31)
Japanese 176.2 KB
2025-03-27 06:07
AGM Information
臨時報告書
Japanese 25.6 KB
2025-03-26 08:00
Registration Form
確認書
Japanese 8.1 KB
2025-03-26 08:00
Governance Information
内部統制報告書-第24期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-26 07:59
Annual Report
有価証券報告書-第24期(2024/01/01-2024/12/31)
Japanese 827.2 KB
2024-08-14 08:15
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-14 08:14
Interim / Quarterly Report
半期報告書-第24期(2024/01/01-2024/06/30)
Japanese 181.4 KB
2024-05-15 08:19
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-15 08:19
Quarterly Report
四半期報告書-第24期第1四半期(2024/01/01-2024/03/31)
Japanese 145.1 KB
2024-03-28 07:11
AGM Information
臨時報告書
Japanese 22.0 KB
2024-03-28 07:08
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:07
Governance Information
内部統制報告書-第23期(2023/01/01-2023/12/31)
Japanese 22.2 KB
2024-03-28 07:04
Annual Report
有価証券報告書-第23期(2023/01/01-2023/12/31)
Japanese 875.2 KB

Automate Your Workflow. Get a real-time feed of all CellSeed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CellSeed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CellSeed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lipidor AB Logo
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.